AC IMMUNE SA Reports Q2 FY2023 Earnings on August 4, 2023

August 26, 2023

☀️Earnings Overview

On August 4 2023, AC IMMUNE SA ($NASDAQ:ACIU) reported its financial results for the second quarter of FY2023, which concluded on June 30 2023. Total revenue for this quarter amounted to CHF 0.0 million, a drop from the same quarter in FY2022 (CHF 0.0 million). The net income of CHF -16.8 million was also lower than the year-ago figure of -19.6 million.

Price History

AC IMMUNE SA reported their Q2 FY2023 earnings on August 4th, 2023 with promising results. On Friday of the same week, the stock opened at $3.1 and closed at $3.0, up by 3.1% from the previous closing price of 2.9. This indicates an upward trend for the company and is a positive sign for investors who have placed faith in the organization. The company also announced plans to use the revenue from this quarter to invest further in research and development, which will help to strengthen their position in the market.

Overall, AC IMMUNE SA’s Q2 FY2023 earnings report has been highly encouraging and reflects the confidence of investors in the company. The increased revenue and net income show that the company is doing well and that they are headed in a positive direction. With plans to continue to invest in R&D, AC IMMUNE SA looks set to continue growing and expanding its operations in the future. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for ACIU. More…

    Total Revenues Net Income Net Margin
    3.94 -66.61 -1690.3%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for ACIU. More…

    Operations Investing Financing
    -61.86 37.48 1.48
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for ACIU. More…

    Total Assets Total Liabilities Book Value Per Share
    156.23 16.9 1.67
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for ACIU are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -56.6% -1687.4%
    FCF Margin ROE ROA
    -1585.2% -28.4% -26.6%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we specialize in analyzing the fundamentals of companies to help investors make smart and informed decisions. After taking a deep dive into AC IMMUNE SA’s financials, we have rated it as a medium risk investment in terms of financial and business aspects. Our team carefully studied the income sheet, balance sheet, cash flow statement, and financial journal of the company. We detected four risk warnings which might be of interest to potential investors. We urge you to become a registered user of GoodWhale to view these warnings and gain more insight into AC IMMUNE SA’s financials. We hope that our analysis was helpful in aiding your decision-making process! More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company’s lead product candidate, tau aggregation inhibitor therapy (TAI), is in Phase II clinical development for the treatment of Alzheimer’s disease. AC Immune SA has collaborations with Genentech, Inc. and Roche Holding AG. The company was founded in 2000 and is headquartered in Lausanne, Switzerland. Fusion Pharmaceuticals Inc, Design Therapeutics Inc, and Qualigen Therapeutics Inc are all clinical-stage biopharmaceutical companies focused on the development of therapeutics for the treatment of neurodegenerative diseases associated with protein misfolding.

    – Fusion Pharmaceuticals Inc ($NASDAQ:FUSN)

    Fusion Pharmaceuticals Inc has a market cap of 109.34M as of 2022, a Return on Equity of -23.19%. The company develops cancer treatments that harness the power of the body’s immune system to fight cancer cells. The company’s lead product is an antibody-drug conjugate that targets a protein found on the surface of cancer cells.

    – Design Therapeutics Inc ($NASDAQ:DSGN)

    Design Therapeutics Inc is a company that focuses on the design and development of therapeutics for the treatment of genetic diseases. Its market capitalization is 898.51 million as of 2022, and its return on equity is -8.84%. The company’s products are based on the principle that the cause of a disease can be identified and targeted with a specific therapy.

    – Qualigen Therapeutics Inc ($NASDAQ:QLGN)

    Qualigen Therapeutics Inc. is a biopharmaceutical company that focuses on the development and commercialization of immuno-oncology therapeutics. The company’s market cap is 9.31M as of 2022 and its ROE is -83.09%. Qualigen’s lead product candidate is Q-NAP, a novel immuno-oncology therapeutic that is currently being investigated in a Phase 1/2 clinical trial in patients with advanced solid tumors.


    Investing in AC Immune SA has been a mixed bag over the past quarter. The company reported total revenue of CHF 0.0 million for the second quarter of FY2023, a decrease from the same quarter the year prior. Net income decreased from -19.6 million to -16.8 million, indicating a decline in profitability. Despite these results, the stock price moved up on the news.

    Investors should carefully consider all relevant factors before investing in AC Immune SA, as the company’s financial performance has been somewhat inconsistent. Nonetheless, any potential upside could make this an attractive option for those willing to take a risk.

    Recent Posts

    Leave a Comment